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&%%!%'Implications for the use of US in early RA 

#(%#%
)
*
 To assess the prevalence, relationship between and predictors of clinical and 
imaging remission in early rheumatoid arthritis (RA), achieved with treat6to6target 
management in clinical practice. 
+
A prospective observational study was conducted in patients with new6onset RA. 
The treatment target was remission by disease activity score (DAS286CRP<2.6). Twelve 
month outcomes included DAS286CRP remission, DAS446CRP remission, ACR/EULAR 
Boolean remission (BR) and absent or absent/minimal power Doppler activity (PDA) on 
ultrasound (US) of 26 joints (total PDA score=0 or ≤1, respectively). Logistic regression was 
conducted to identify baseline predictors of these outcomes. 

Of 105 patients with complete 126month data, the rate of DAS286CRP remission 
was 43%, DAS446CRP remission was 39%, BR was 14%, absent PDA was 40% and 
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absent/minimal PDA was 57%. Amongst patients achieving clinical remission defined by 
DAS286CRP, DAS446CRP or BR, absence of PDA was observed in 42%, 44% and 40%, 
respectively; absent/minimal PDA was detected in 62%, 66% and 67%, respectively. On 
multivariable analysis, shorter symptom duration, male gender, fewer tender joints and lower 
disability were associated with the clinical remission definitions. Lack of osteoarthritis 
predicted absence of PDA and lower total baseline PDA predicted absent/minimal PDA. 
		DAS286CRP remission and absence of PDA were observed in almost half of 
patients, but less than a quarter achieved both. Achievement of BR was rare. The low 
agreement between any of the clinical and imaging outcomes and differences in their 
predictors highlight the complex interaction between symptoms and synovitis, with 
implications for treat6to6target management. Long6term follow6up should determine the most 
appropriate target. 
,-.Rheumatoid Arthritis, Remission, Ultrasound, Disease Modifying 
Antirheumatic Drug, Prediction, Early Arthritis Clinic, Treatment to Target. 

,-+#"
Following a treat6to6target approach, 43% of patients with RA achieved DAS28 CRP 
remission in clinical practice. 
In RA patients achieving DAS286CRP, DAS446CRP and 2011 ACR/EULAR remission, 
significant power Doppler activity was observed. 
Objective measures of severe RA at baseline were associated with ongoing power Doppler 
at 12 months. 
 
! %$%! 
Trials reveal patients with early rheumatoid arthritis (RA) achieve superior outcomes with 
treatment to target strategies in comparison to conventional routine care [163]. European 
League Against Rheumatism (EULAR) guidelines recommend this approach [4, 5]. 
Recommendations include monitoring disease activity using a composite measure at least 
every 3 months, with optimisation of treatment to achieve a pre6defined target, primarily 
remission. In 2011, American College of Rheumatology (ACR)/EULAR remission criteria 
were developed for use in trials [6] and are now recommended as the optimal target for 
treatment [4]. Two definitions are proposed, based on the simplified disease activity index 
(SDAI≤3.3) or that developed using a Boolean approach: swollen joint count (SJC), tender 
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joint count (TJC), C6reactive protein (CRP, mg/dl), and patient global self6assessment (0610 
scale) all ≤1.  
Such clinical definitions of remission may be imperfect in delineating patients with true 
absence of inflammation. Data indicates approximately half of patients achieving SDAI 
remission and one third of patients achieving Boolean remission (using a 286joint count), 
after 12 months of treatment with methotrexate, experience worsening radiographic scores 
and/or a decrease in physical functioning over the following 12 months[6], highlighting the 
need for ongoing monitoring. Imaging studies in patients with established RA confirm that 
despite achievement of a clinical remission state, subclinical synovitis may persist. In 
patients achieving Boolean remission, power Doppler activity (PDA) was demonstrated in 
approximately half of patients on ultrasound examination of the dominant hand and wrist[7] 
and one third of patients within 22 joints (hands, wrists, elbows and knees)[8]. The relevance 
of PDA in clinical remission and low disease activity states is evident from its relationship 
with radiographic progression [9, 10] and future disease flare [10612]. Conversely, studies 
suggest the clinical remission criteria may be too stringent in a subset of patients, notably 
those with comorbidities[13].  
Ultrasound, by directly assessing the pathology of RA, may enable a more comprehensive 
approach to defining remission which could guide therapeutic decisions. Imaging remission 
has been proposed as a goal for therapy[14], supported by a recent study demonstrating a 
superior rate of disease activity score (DAS44) remission at 18 months in patients receiving 
treatment targeted to ultrasound remission in comparison to a target of DAS28 low disease 
activity[15]. Further studies are proposed[16]. 
Evidence of success of treat6to6target strategies in unselected patients with early RA in 
clinical practice remains limited[17620] and data regarding the relationship between clinical 
and imaging remission in early disease, in particular with respect to the new 2011 
ACR/EULAR Boolean criteria, is lacking. Several studies have examined predictors of 
clinical remission in observational, open6label and randomised studies[19, 21626]; however, 
less is understood regarding the predictors of clinical and imaging remission in daily practice 
which may ultimately facilitate decisions regarding choice of first6line therapy or treatment 
strategy for individual patients. 
We conducted an observational study to assess how the EULAR treat6to6target guidelines, 
and the paradigm for targeting clinical remission, translate into clinical practice particularly in 
relation to imaging. The objectives were to evaluate, in early RA, the rates of DAS28 
remission, DAS44 remission, 2011 ACR/EULAR Boolean remission and imaging remission, 
and the agreement between these clinical remission states and imaging remission. An 
additional aim was to establish predictors of these outcomes. 
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A prospective observational study was conducted in patients with new6onset inflammatory 
arthritis (IA) attending the Leeds Early Arthritis Clinic. The study was approved by the Leeds 
Regional Ethics Committee. All participants provided written consent for inclusion according 
to the declaration of Helsinki. Patients were managed according to EULAR treat6to6target 
recommendations when clinically appropriate. The target was remission defined by DAS28 
using 4 variables (DAS286CRP4v<2.6): SJC28, TJC28, CRP and patient visual analogue 
scale disease assessment (VASDA). This was selected due to its frequent use in clinics, 
prior to publication of 2011 ACR/EULAR remission criteria, with preference of CRP over 
erythrocyte sedimentation rate (ESR) due to the dependency of ESR on age and gender[27]. 
As this definition of remission may allow persistence of swollen joints[28], consultant 
impression of disease remission also factored in treatment decisions, in accordance with 
guidelines[5]. Treatment escalation to biologic therapy was as recommended by the National 
Institute of Clinical Excellence (NICE), i.e. at least high disease activity (DAS28>5.1) after 
failure of at least two synthetic disease6modifying drugs (DMARDs) including methotrexate.  
Criteria for inclusion were enrolment between June 2010 and September 2012, fulfilment of 
RA criteria (1987 ACR and/or 2010 ACR/EULAR RA classification criteria) and 
DAS286CRP4v≥2.6 at baseline (or in the instance of missing patient VASDA, 
DAS286CRP3v≥2.6 [DAS28 based on 3 variables: SJC28, TJC28 and CRP]). Exclusions 
were patients not receiving DMARDs within 3 months of baseline (for example due to 
contraindications), receiving an alternative non6RA diagnosis within the following 12 months 
or with missing 126month outcome data. Inclusion of patients with coexistent osteoarthritis 
(according to a consultant rheumatologist diagnosis, i.e. consistent symptoms and/or signs) 
was permitted due to the prevalence of these findings. 

	#

	
Clinical data collection occurred every three months (or as clinically indicated, in accordance 
with EULAR guidelines[5]). Assessments included examination of 44 joints for swelling and 
53 joints for tenderness (including Ritchie Articular Index, RAI) by rheumatologists and 
rheumatology nurse6specialists.  
Adherence to guidelines was assessed by calculating the proportion of patients in whom 
DAS286CRP4v was recorded at least every 3 months until achievement of the target 
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(DAS286CRP4v<2.6) and DMARD or corticosteroid treatment was escalated at least every 3 
months if the target was not met. Escalation in DMARD therapy was defined as addition or 
switch of synthetic (methotrexate, sulphasalazine, hydroxychloroquine or leflunomide) or 
biologic DMARD, an increase in dose of DMARD or enrolled in a biologic clinical trial. 
Corticosteroid treatment escalation included initiation of, or increase in, oral prednisolone, 
administration of intramuscular, intra6articular or intravenous methylprednisolone, or 
intramuscular triamcinolone. 
 
$	
Ultrasound examination of 26 joints (elbows, wrists, second and third metacarpophalangeal 
[MCP] and proximal interphalangeal [PIP] joints, knees, ankles and metatarsophalangeal 
[MTP] joints) was performed at baseline and 12 months. Joints were selected on the basis of 
the frequency of US involvement previously reported in RA[29]. A reduced joint assessment 
in comparison to the number of joints assessed clinically was conducted in order to optimise 
feasibility.  
Ultrasound was carried out in a routine out6patient setting by a validated sonographer who 
had undergone training with RJW (experienced EULAR teacher) and who was blinded to the 
clinical findings. The same machine (GE E9) was used, employing either a 1568 or 1868 MHz 
linear array transducer. Scoring was performed according to a standard operating procedure 
showing probe positions and scoring scenarios utilising the EULAR/Outcome Measures in 
Rheumatology Clinical Trials (OMERACT) system.Grey scale synovitis (GS) and PDA at 
each joint was graded using a previously reported semi6quantitative scale of zero to 
three[30]. Total GS and PDA scores were calculated for each patient by summation of the 
respective semi6quantitative scores (063) at all 26 joints (maximum total score 78).  
 
	

These were DAS286CRP4v remission (DAS286CRP4v <2.6) and low disease activity 
(DAS286CRP4v<3.2), DAS446CRP4v remission (DAS446CRP4v<1.6) and low disease 
activity (DAS446CRP4v<2.4) and 2011 ACR/EULAR Boolean remission (SJC44≤1, 
TJC53≤1, CRP≤10mg/dL and patient VASDA≤10mm). 
 
!	

Absence of PDA was defined as total PDA score=0. In order to allow for low6level PDA 
which may be observed, particularly at the wrist and first MTP joints, in healthy 
individuals[31635] and/or patients with osteoarthritis[36, 37], the following definitions of 
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absent/minimal PDA were also considered: total PDA score≤1 (i.e. presence of a maximum 
of grade 1 PDA in a maximum of any one of the 26 joints) or total PDA score≤1 excluding 
low6grade PDA (PDA=grade 1) at the wrists and first MTPs (i.e. presence of a maximum of 
grade 1 PDA in the wrists and/or first MTPs and any one of the following joints: elbow, 
MCP263, PIP263, knee, ankle or MTP265 joints).  


Characteristics were described using frequencies for categorical variables and means and 
standard deviations (SD) for continuous variables following a normal distribution. For 
non6parametric data, medians and interquartile ranges (IQR) were calculated. To determine 
any difference between patients included in analyses and those excluded due to missing 
data, Chi6squared tests (or Fisher’s exact tests when appropriate according to the number of 
expected values) for categorical variables, t6tests for continuous variables following a normal 
distribution and Mann6Whitney6U tests for non6parametric variables were performed.  
Prevalence and bias adjusted kappa statistics were calculated to examine the relationship 
between the clinical remission endpoints and imaging outcomes. Univariable logistic 
regression was conducted to investigate factors associated with the clinical remission and 
imaging outcomes. Multivariable logistic regression analysis was also planned, entering 
baseline variables demonstrating statistical significance (p<0.05) on univariable analysis. 

$'%

	
Two6hundred and seventeen patients were eligible for inclusion in the analysis (Figure 1). No 
significant difference was observed between baseline DAS286CRP scores, DAS446CRP 
scores or ultrasound parameters in patients included in the analyses (n=105) and those who 
were lost to follow6up or in whom data was missing (n=112). However, they differed 
significantly (p<0.05) in the following manner: mean age was higher and SJC28, TJC28, 
SJC44 and RAI were generally lower amongst included patients (Table 1). 

+	

	
The majority of patients commenced DMARDs at baseline (72%) or within the first 4 weeks 
(15%). Choice of first DMARD was methotrexate in 86%, hydroxychloroquine in 10% and 
sulphasalazine in 4% of patients. Methotrexate in combination with another DMARD was 
commenced in the remaining 1%. A contraindication to methotrexate was apparent in 5% of 
patients, including chronic obstructive airways disease, recent or concurrent infection and 
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deranged liver function tests. Over 12 months, 9 (9%) and 20 (19%) patients failed treatment 
with methotrexate or an alternative DMARD, respectively, due to intolerance or an adverse 
event. Table 2 provides further details of patient management.   
The DAS286CRP4v score was recorded at least every 3 months up to 12 months, or until the 
target was met, in 76 (72%) patients. Escalation of DMARDs (excluding corticosteroids) was 
appropriate (i.e. at least every 3 months if DAS286CRP4v≥2.6) in 53/76 (70%) of these 
patients. In a further 8 (10%) patients, corticosteroid therapy was escalated at least 
36monthly. Amongst the remaining 15 patients in whom treatment was not escalated despite 
awareness of DAS286CRP4v≥2.6, reasons throughout the 12 months were: awaiting effect 
of previous treatment escalation (n=6), non6inflammatory symptoms only (n=5), acceptable 
disease control (n=4), contraindication to treatment escalation (n=2), patient declined (n=2), 
considered for biologic clinical trial (n=2) and isolated flare (n=1).  
As the target DAS286CRP4v<2.6 allows the presence of clinical swelling[28], there is still a 
role for clinical assessment as recommended within EULAR guidelines. In fact, out of 158 
visits at which DAS286CRP4v<2.6 was observed, DMARD treatment was escalated due to a 
clinician impression of ongoing inflammatory disease activity at 26 (16%) visits.
 


At 12 months, rates of DAS286CRP4v remission (DAS286CRP4v<2.6) and low disease 
activity (DAS286CRP4v<3.2) were 43% and 60%; rates of DAS446CRP4v remission 
(DAS446CRP4v<1.6) and low disease activity (DAS446CRP4v<2.4) were 39% and 73%.  
The rate of 2011 ACR/EULAR Boolean remission was 14%. The thirty patients achieving 
DAS286CRP4v<2.6 but not meeting the Boolean definition of remission missed the latter due 
to patient VASDA>10mm (n=23), TJC>1 (n=9), SJC>1 (n=6) and/or CRP>10mg/L (n=6).  
In respect to ultrasound, absence of PDA (total PDA score=0) was observed in 42 (40%) 
patients at 12 months.  Absent/minimal PDA, defined by a total PDA≤1, was observed in 60 
(57%) patients. If any low6grade PDA (grade 1) at the wrists and/or first MTP joints was also 
accepted within the definition, seven additional patients achieved minimal PDA; i.e. 64% of 
patients demonstrated a total PDA score ≤1 excluding PDA=grade 1 at individual wrist and 
first MTP joints. 
Amongst 70 patients attaining DAS286CRP4v<2.6 at least once over the 12 months, the 
median (IQR) time to first achievement of DAS286CRP4v<2.6 was 6 (369) months. In 
patients achieving DAS286CRP4v remission prior to month 12 (n=61), first DAS286CRP4v 
remission was sustained over the remaining follow6up in 27 (44%) patients. The majority of 
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these patients achieved DAS286CRP4v remission within the first 6 months; 41% and 70% 
achieved remission by month 3 and month 6, respectively. 
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Prevalence and bias adjusted kappa statistics illustrate poor agreement between the clinical 
and imaging outcomes (Table 3). In patients achieving the various definitions of clinical 
remission at 12 months, absence of PDA (total PDA score=0) was observed in 19/45 (42%) 
patients achieving DAS286CRP4v<2.6, 18/41 (44%) patients achieving DAS446CRP4v<1.6, 
and 6/15 (40%) patients achieving Boolean remission. Absent/minimal PDA (total PDA 
score≤1) was observed in 28/45 (62%), 27/41 (66%) and 10/15 (67%) patients, respectively. 
With exclusion of low6grade PDA (grade 1) at the wrists and/or first MTP joints, 
absent/minimal PDA was observed in 31/45 (69%) and 29/41 (71%) of patients achieving 
DAS286CRP4v and DAS446CRP4v remission, respectively, whilst rate amongst patients 
achieving Boolean remission was unchanged. 
In patients achieving DAS286CRP4v<2.6 with ongoing imaging evidence of synovitis (n=26), 
PDA was observed at the following sites: wrists (n=16), MCP263 (n=13), MTP1 (n=4), MTP26
5 (n=4), PIP263 (n=4), elbows (n=2) and the knee (n=1).  In patients achieving Boolean 
remission the following joint regions were affected by PDA: MCP263 (n=5), wrists (n=4), 
MTP265 (n=1), PIP263 (n=1), and elbows (n=1). 
In patients lacking any PDA, but with active disease as indicated by DAS286CRP4v≥2.6 
(n=23), median (IQR) values for the DAS28 component variables were TJC28 5(269), SJC28 
1(062), patient VASDA 57(40657) mm and CRP 9(0618) mg/dL. Amongst 36 patients lacking 
any PDA but not achieving Boolean remission, patient VASDA>10mm was the most frequent 
preclusion to fulfilment of the Boolean criteria (n=32), followed by TJC53>1 (n=24), 
CRP>10mg/dL (n=15) and SJC44>1 (n=9). 


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	!	

Univariable analyses demonstrated achievement of the various clinical remission outcomes 
was significantly associated with male gender, shorter symptom duration, fewer tender joints 
and lower HAQ at baseline (Table 4). In comparison, baseline parameters predictive of 
achievement of imaging outcomes were lack of coexistent osteoarthritis, seronegativity, 
fewer swollen joints, lower CRP and lower total PDA score on ultrasound. A lower 
DAS286CRP3v score at baseline was significantly associated with all outcomes. Excluding 
PDA=grade 1 at the wrists and/or first MTP joints in the definition of absent/minimal PDA did 
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not significantly affect the results, therefore only results for total PDA score≤1 amongst all 26 
joints are presented.  
Results of multivariable analysis, entering baseline variables demonstrating statistical 
significance (p<0.05) on univariable analysis, are shown in Table 5. The composite score 
(DAS286CRP) was assessed in univariable analyses, but not in multivariable analysis, 
because of overlap with its component variables. 
 
!$! 
This large single6centre, contemporary study reveals that at 12 months almost half of 
patients with new6onset RA achieve the clinical target (DAS286CRP remission) in daily 
practice, using EULAR treatment6to6target recommendations as a guide to management. 
The rate of 2011 ACR/EULAR Boolean remission was significantly lower. In patients 
achieving a state of clinical remission, regardless of the outcome measure used to define 
remission (either DAS28, DAS44 or even 2011 ACR/EULAR Boolean remission), any PDA 
(total PDA score >0) was observed in at least half and significant PDA (total PDA score >1) 
was apparent in around one third of patients. 
The clinical remission rates are consistent with other observational treat6to6target RA cohorts 
including the multicentre Dutch Rheumatoid Arthritis Monitoring (DREAM) cohort (DAS28 
remission and 2011 ACR/EULAR Boolean remission observed in 58%[17] and 21%[38], 
respectively) and an Italian early arthritis clinic (DAS44 remission in 46%)[19]. Methods of 
assessment in the DREAM study included 28 joint examination and patient assessment of 
general health, and it is not clear whether patients’ global assessments of disease or more 
extensive joint examination was available in the assessment of 2011 ACR/EULAR Boolean 
remission. In the DREAM study, non6adherence to intensifying treatment in appropriate 
patients was observed in 35% of visits, with the most frequent reasons being a physician 
impression of clinical remission followed by side6effects[18], which is comparable to our 
findings. 
Importantly, this is the first study to demonstrate the discordance between DAS28 remission, 
or the more stringent 2011 ACR/EULAR Boolean definition of remission, and imaging 
remission in early RA. It confirms findings previously reported in smaller studies of patients 
with early RA achieving DAS44 remission using a DAS446steered treatment protocol 
(including methotrexate and TNF6inhibitor therapy): persistence of any PDA was identified in 
42% of 48 patients amongst 10 joints (the wrists, second and third MCPs and PIPs)[39], and 
41% of 43 patients using a 446joint ultrasound assessment[12]. Other groups have reported 
ongoing PDA in patients with established RA across various definitions of clinical remission 
including DAS28[7, 8, 30, 40, 41], DAS44[10, 39] and 2011 ACR/EULAR Boolean6defined 
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remission[7, 8], in the hands[7, 30, 39, 42, 43] or amongst more extensive joint 
assessments[8, 10, 40, 41]. Issues of face validity of the clinical composite measures as 
indicators of remission, which have previously been raised in established RA, are therefore 
pertinent to early RA and the current recommended treatment strategy of targeting clinical 
remission.  
A significant proportion of patients with absent or absent/minimal PDA had evidence of 
clinical disease activity as measured by DAS286CRP, DAS446CRP and non6fulfilment of 
2011 ACR/EULAR Boolean remission criteria. It is likely, at least for a subset of these 
patients, that the standardised 266joint ultrasound assessment missed active joint 
inflammation in other joints (e.g. hips, shoulders, MCP365, PIP365). However, reduced 
ultrasound joint assessments including the elbows, wrists, second and third MCPs, knees, 
ankles and second to fifth MTPs have previously been shown to correlate well with 
ultrasound assessment of 44 joints in both patients in clinical remission[40] and those with 
active disease[44]. Moreover, the likelihood that the presence of tender joints and a high 
patient global assessment which may be influenced by a complex interaction of factors other 
than active synovitis (such as chronic pain, side6effects of treatment and the presence of 
comorbidity) is also relevant, particularly given the characteristics which were evident in 
these patients.  
Baseline predictors of clinical remission outcomes were male gender, shorter symptom 
duration, fewer tender joints, and lower patient VASDA and HAQ scores. In contrast, lack of 
osteoarthritis and objective signs of less severe disease (RF and ACPA negativity, fewer 
clinically swollen joints, and lower CRP and baseline PDA) were associated with favourable 
imaging outcomes. The latter parameters are arguably more reflective of the primary 
pathology, active synovitis. Therefore, logically, they should warrant aggressive treatment or 
treatment escalation if present or if increased above normal levels. These findings, therefore, 
support current and future research into the use of imaging within the management of early 
RA. 
The strengths of this study are its considerable size for a single6centre study. All assessors 
were trained, supervised and working within one clinic, limiting variation in prescribing 
behaviour. Management and data collection conducted in an out6patient clinic setting and 
the absence of strict inclusion criteria afford a degree of generalisability to daily practice. Of 
note, the prevalence of comorbidities was significant. Greater than one in ten patients in this 
real6life cohort displayed a contraindication to commencement of methotrexate or intolerance 
to it necessitating cessation. In addition, one in twenty patients failed an alternative DMARD 
to methotrexate.  
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Despite the planned prospective data collection, a proportion of patients were excluded due 
to missing data, a significant drawback to this study method. The significantly higher SJC28, 
TJC28 and RAI of patients with missing follow6up data in comparison to patients included in 
analyses may be related to the proportion of patients who were subsequently referred to 
biologics clinical trials or received biologic DMARDs with follow6up in biologics monitoring 
clinic in which standardised ultrasound does not form part of routine assessments. Loss to 
follow6up of patients with more severe disease may have falsely elevated the remission rates 
observed. Limitations in the interpretation of PDA findings must be borne in mind, including 
its validity in differentiating RA synovitis from findings in healthy joints[31, 32, 35, 41], 
particularly in the wrist[32, 41], or those attributable to osteoarthritis[35637]. Nonetheless, 
prognostic validity of PDA in clinical remission has been demonstrated in relation to the 
prediction of disease flare[10612] and radiographic progression[9, 10]. 
This study provides insights into the translation of treat6to6target within clinical practice. It 
highlights the difficulties in data collection and adhering to treat6to6target guidelines in a 
clinical setting and identifies room for improving the outcomes of patients with early RA. A 
clinically significant proportion of patients achieving DAS28, DAS44 or 2011 ACR/EULAR 
Boolean remission (now recommended for use as a target for treatment by EULAR) 
demonstrate PDA on ultrasound. More accurate measurement of inflammatory activity by 
ultrasound should perhaps be a key determinant in guiding treatment escalation and 
assessing true absence of disease activity. The differences observed between the disease 
characteristics at baseline which predicted clinical and imaging remission provide further 
support for the ongoing investigation into the use of imaging within a treat6to6target strategy; 
patients with unfavourable subjective factors were less likely to achieve the clinical remission 
outcomes, whereas factors more directly indicative of inflammatory disease activity predicted 
persistent active disease on imaging. Failure to achieve absent/minimal PDA was associated 
with higher PDA at baseline. As persistence of PDA in clinical remission is associated with 
poor outcomes[9611] the baseline PDA is a warning. Ultrasound may therefore prove to be a 
useful tool in discerning an individual’s prognosis at diagnosis as well as assessing 
inflammation on treatment.  

#, .'"+ %
We acknowledge other members of the Leeds Musculoskeletal Biomedical Research Unit for 
their contribution to data collection, including sonographers Laura Horton and Alwyn 
Jackson, and Elizabeth Hensor for statistical advice. 

Page 12 of 21Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
!'$%#%+ %The authors have declared no conflicts of interest. 

/$ ! "This research was part funded by the National Institute for Health Research 
(NIHR) through the Leeds Musculoskeletal Biomedical Research Unit and Arthritis Research 
UK through the Programme Grant "Accurate phenotyping in early arthritis to improve 
prognosis and prevent evolution to rheumatoid arthritis". 

/ 
 
1 Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for 
rheumatoid arthritis (the TICORA study): a single6blind randomised controlled trial. The 
Lancet 2004;364(9430):26369. 
2 Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with 
methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted 
Management in Early Rheumatoid Arthritis (CAMERA, an open6label strategy trial). Ann. 
Rheum. Dis. 2007;66(11):144369. 
3 Knevel R, Schoels M, Huizinga TWJ, et al. Current evidence for a strategic approach 
to the management of rheumatoid arthritis with disease6modifying antirheumatic drugs: a 
systematic literature review informing the EULAR recommendations for the management of 
rheumatoid arthritis. Ann. Rheum. Dis. 2010;69(6):987694. 
4 Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the 
management of rheumatoid arthritis with synthetic and biological disease6modifying 
antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014;73(3):4926509. 
5 Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: 
recommendations of an international task force. Ann. Rheum. Dis. 2010;69(4):63167. 
6 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European 
League Against Rheumatism provisional definition of remission in rheumatoid arthritis for 
clinical trials. Arthritis Rheum. 2011;63(3):573686. 
7 Saleem B, Brown AK, Keen H, et al. Should imaging be a component of rheumatoid 
arthritis remission criteria? A comparison between traditional and modified composite 
remission scores and imaging assessments. Ann. Rheum. Dis. 2011;70(5):79268. 
8 Zufferey P, Möller B, Brulhart L, et al. Persistence of ultrasound synovitis in patients 
with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission 
definitions: Results of an observational cohort study. Joint Bone Spine 2014;81(5):426632. 
9 Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent 
dissociation between clinical remission and continued structural deterioration in rheumatoid 
arthritis. Arthritis Rheum. 2008;58(10):2958667. 
10 Foltz V, Gandjbakhch F, Etchepare F, et al. Power Doppler ultrasound, but not low6
field magnetic resonance imaging, predicts relapse and radiographic disease progression in 
rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum. 
2012;64(1):67676. 
11 Saleem B, Brown AK, Quinn M, et al. Can flare be predicted in DMARD treated RA 
patients in remission, and is it important? A cohort study. Ann. Rheum. Dis. 
2012;71(8):1316621. 
12 Scirè CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. 
Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical 
remission: power Doppler signal predicts short6term relapse. Rheumatology 
2009;48(9):109267. 
Page 13 of 21 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 Thiele K, Huscher D, Bischoff S, et al. Performance of the 2011 ACR/EULAR 
preliminary remission criteria compared with DAS28 remission in unselected patients with 
rheumatoid arthritis. Ann. Rheum. Dis. 2013;72(7):119469. 
14 van der Heijde D. Remission by imaging in rheumatoid arthritis: should this be the 
ultimate goal? Ann. Rheum. Dis. 2012;71(Suppl 2):i896i92. 
15 Dale J, Stirling A, McInnes IB, Porter D. Targeting ultrasound remission in early 
rheumatoid arthritis – results of the Taser study (abstract). In: 	


. San Diego, USA. 
16 Wakefield RJ, D'Agostino MA, Naredo E, et al. After treat6to6target: can a targeted 
ultrasound initiative improve RA outcomes? Postgrad. Med. J. 2012;88(1042):48266. 
17 Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat6to6target strategy 
in very early rheumatoid arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring 
remission induction cohort study. Arthritis Rheum. 2011;63(10):2865672. 
18 Vermeer M, Kuper H, Bernelot Moens H, et al. Adherence to a treat6to6target strategy 
in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res. 
Ther. 2012;14(6):R254. 
19 Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G. Very early 
rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and 
radiographic non6progression. Ann. Rheum. Dis. 2011;70(7):129265. 
20 van Hulst LTC, Creemers MCW, Fransen J, et al. How to improve DAS28 use in daily 
clinical practice?—a pilot study of a nurse6led intervention. Rheumatology 2010;49(4):74168. 
21 Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early 
rheumatoid arthritis: a multiparameter prospective study. Ann. Rheum. Dis. 2004;63(6):6756
80. 
22 Contreras6Yanez I, Rull6Gabayet M, Pascual6Ramos V. Early disease activity 
suppression and younger age predict excellent outcome of recent6onset rheumatoid arthritis 
patients treated with conventional disease modifying anti6rheumatic drugs. Clin. Exp. 
Rheumatol. 2012;30(3):40268. 
23 Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and 
induction of remission using single6drug or combination–disease6modifying antirheumatic 
drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;46(4):89468. 
24 Ma MHY, Ibrahim F, Walker D, et al. Remission in Early Rheumatoid Arthritis: 
Predicting Treatment Response. J. Rheumatol. 2012;39(3):47065. 
25 Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor 
of remission: a multicentre real life prospective study. Ann. Rheum. Dis. 2012. 
26 Wevers6de Boer K, Visser K, Heimans L, et al. Remission induction therapy with 
methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis 
(the IMPROVED study). Ann. Rheum. Dis. 2012;71(9):147267. 
27 Crowson CS, Rahman MU, Matteson EL. Which Measure of Inflammation to Use? A 
Comparison of Erythrocyte Sedimentation Rate and C6Reactive Protein Measurements from 
Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis. J. Rheumatol. 
2009;36(8):1606610. 
28 Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to 
assess remission in rheumatoid arthritis? Ann. Rheum. Dis. 2005;64(10):141063. 
29 Naredo E, Gamero F, Bonilla G, Uson J, Carmona L, Laffon A. Ultrasonographic 
assessment of inflammatory activity in rheumatoid arthritis: comparison of extended versus 
reduced joint evaluation. Clin. Exp. Rheumatol. 2005;23(6):88164. 
30 Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid 
arthritis patients with disease6modifying antirheumatic drug–induced clinical remission: 
Evidence from an imaging study may explain structural progression. Arthritis Rheum. 
2006;54(12):3761673. 
31 Millot F, Clavel G, Etchepare F, et al. Musculoskeletal ultrasonography in healthy 
subjects and ultrasound criteria for early arthritis (the ESPOIR cohort). J. Rheumatol. 
2011;38(4):613620. 
Page 14 of 21Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
32 Terslev L, Torp6Pedersen S, Qvistgaard E, von der Recke P, Bliddal H. Doppler 
ultrasound findings in healthy wrists and finger joints. Ann. Rheum. Dis. 2004;63(6):64468. 
33 Carotti M, Salaffi F, Morbiducci J, et al. Colour Doppler ultrasonography evaluation of 
vascularization in the wrist and finger joints in rheumatoid arthritis patients and healthy 
subjects. Eur. J. Radiol. 2012;81(8):183468. 
34 Kitchen J, Kane D. Greyscale and power Doppler ultrasonographic evaluation of 
normal synovial joints: correlation with pro6 and anti6inflammatory cytokines and angiogenic 
factors. Rheumatology 2015;54(3):458662. 
35 Hameed B, Pilcher J, Heron C, Kiely PDW. The relation between composite 
ultrasound measures and the DAS28 score, its components and acute phase markers in 
adult RA. Rheumatology 2008;47(4):476680. 
36 Mathiessen A, Slatkowsky6Christensen B, Kvien TK, Hammer HB, Haugen IK. 
Ultrasound6detected inflammation predicts radiographic progression in hand osteoarthritis 
after 5 years. Ann. Rheum. Dis. 2015. 
http://ard.bmj.com/content/early/2015/04/01/annrheumdis620156207241.abstract Accessed 
April 1 2015. 
37 Keen HI, Wakefield RJ, Grainger AJ, Hensor EMA, Emery P, Conaghan PG. An 
ultrasonographic study of osteoarthritis of the hand: Synovitis and its relationship to 
structural pathology and symptoms. Arthritis Care Res. 2008;59(12):1756663. 
38 Vermeer M, Kuper HH, Moens HJB, et al. Sustained Beneficial Effects of a 
Protocolized Treat6to6Target Strategy in Very Early Rheumatoid Arthritis: Three6Year Results 
of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. Arthritis Care Res. 
2013;65(8):1219626. 
39 Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical and 
ultrasonographic remission determines different chances of relapse in early and long 
standing rheumatoid arthritis. Ann. Rheum. Dis. 2011;70(1):17265. 
40 Naredo E, Valor L, De la Torre I, et al. Ultrasound Joint Inflammation in Rheumatoid 
Arthritis in Clinical Remission: How Many and Which Joints Should Be Assessed? Arthritis 
Care Res. 2013;65(4):51267. 
41 Balsa A, de Miguel E, Castillo C, Peiteado D, Martín6Mola E. Superiority of SDAI over 
DAS628 in assessment of remission in rheumatoid arthritis patients using power Doppler 
ultrasonography as a gold standard. Rheumatology 2010;49(4):683690. 
42 Gärtner M, Mandl P, Radner H, et al. Sonographic Joint Assessment in Rheumatoid 
Arthritis: Associations With Clinical Joint Assessment During a State of Remission. Arthritis 
Rheum. 2013;65(8):2005614. 
43 Salih Ozgocmen MD, Huseyin Ozdemir MD, Adem Kiris MD, Zulkif Bozgeyik MD, 
Ozge Ardicoglu MD. Clinical Evaluation and Power Doppler Sonography in Rheumatoid 
Arthritis: Evidence for Ongoing Synovial Inflammation in Clinical Remission. South. Med. J. 
2008;101(3):24065. 
44 Naredo E, Rodríguez M, Campos C, et al. Validity, reproducibility, and 
responsiveness of a twelve6joint simplified power doppler ultrasonographic assessment of 
joint inflammation in rheumatoid arthritis. Arthritis Care Res. 2008;59(4):515622. 
45 Koski JM, Saarakkala S, Helle M, et al. Assessing the intra6 and inter6reader 
reliability of dynamic ultrasound images in power Doppler ultrasonography. Ann. Rheum. 
Dis. 2006;65(12):1658660. 
46 Wakefield RJ, Brown AK, O'Connor PJ, Emery P. Power doppler sonography: 
Improving disease activity assessment in inflammatory musculoskeletal disease. Arthritis 
Rheum. 2003;48(2):28568. 
47 Joshua F, De Carle R, Rayment M, et al. Power Doppler ‘blanching’ after the 
application of transducer pressure. Australas. Radiol. 2005;49(3):218621. 
48 Torp6Pedersen ST, Terslev L. Settings and artefacts relevant in colour/power 
Doppler ultrasound in rheumatology. Ann. Rheum. Dis. 2008;67(2):14369. 
49 Ellegaard K, Torp6Pedersen S, Henriksen M, Lund H, Danneskiold6Samsøe B, 
Bliddal H. Influence of recent exercise and skin temperature on ultrasound Doppler 
Page 15 of 21 Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
measurements in patients with rheumatoid arthritis—an intervention study. Rheumatology 
2009;48(12):152063. 
50 Strunk J, Strube K, Klingenberger P, Müller6Ladner U, Lange U. Two6 and three6
dimensional Doppler sonographic evaluation of the effect of local cryotherapy on synovial 
perfusion in wrist arthritis. Rheumatology 2006;45(5):637640. 
51 Lee V, Zayat A, Wakefield RJ. The effect of joint position on Doppler flow in finger 
synovitis. Ann. Rheum. Dis. 2009;68(4):60364. 
52 Zayat AS, Freeston JE, Conaghan PG, Hensor EMA, Emery P, Wakefield RJ. Does 
joint position affect US findings in inflammatory arthritis? Rheumatology 2012;51(5):92165. 
53 Bruyn GAW, Naredo E, Möller I, et al. Reliability of ultrasonography in detecting 
shoulder disease in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2009;68(3):357661. 
54 D'Agostino MA, Wakefield R, Filippucci E, et al. Intra6 and inter6observer reliability of 
ultrasonography for detecting and scoring synovitis in rheumatoid arthritis: a report of a 
EULAR ECSISIT task force (abstract). Ann. Rheum. Dis. 2005;64(Suppl III):62. 
 
  
Page 16 of 21Rheumatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
/
0
		
 
 
 


!#
	1220

		
	1304
 
Exclusions n=160 
  No swelling (n=52) 
  Declined consent (n=18) 
  Not attending (n=11) 
  Alternative diagnosis (not fulfilling 2010 
ACR/EULAR and/or 1987 ACR RA 
classification criteria) (n=76)  
  Other (n=3) 
Other exclusions n=64 
  No DMARD within 3 months (n=18)  
  DAS286CRP<2.6 at baseline or time of 
DMARD commencement (n=17) 
  Referred to biologic clinical trial (n=16) 
  Alternative non6RA diagnosis within 12 
months follow6up (n=11) 
  DAS286CRP not known (n=2) 
#
	

	1350
03+	
	1067
Loss to follow6up n=25 
Did not attend n=14 
Biologic clinical trial n=6 
Died n=3 
Moved out of area n=1 
Reason unknown n=1 
 
Incomplete outcome data n=87 
Clinical data incomplete n=67 
Ultrasound data incomplete n=71 
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 Included in analysis Excluded due to 
missing follow6up data 
p 
 
(n=105) 
Missing 
Values 
(n=112) 
Missing 
Values 
Age, mean (SD), years 59 (13) 6 53 (15) 6 6663
Female, N (%) 79 (75) 6 80 (71) 6 0.5 
BMI, mean (SD) 27 (5) 13 29 (6) 12 0.1 
Symptom duration,  median 
(IQR), months 
6 (4613) 6 7 (4613) 6 0.5 
Current/previous smoker, N (%)      65 (62%) 6 67 (60%) 1 0.8 
Number of comorbidities
a
, N (%) 
        1 
2 
3 
≥4 
 
34 (32%) 
19 (18%) 
15 (14%) 
7 (7%) 
6 
 
25 (22%) 
31 (28%) 
14 (13%) 
7 (6%) 
6 
 
0.9 
History/current evidence of 
coexistent osteoarthritis
b
, N (%)
 46 (44%) 6 37 (33%) 6 0.1 
RF positive, N (%) 
ACPA positive, N (%) 
78 (74%) 
81 (77%) 
6 
6 
72 (64%) 
73 (65%) 
6 
6 
0.1 
0.05 
Fulfilment of RA classification 
criteria, N (%)                
1987 ACR RA 
2010 ACR/EULAR RA
 
 
 
73 (70%) 
101 (96%) 
 
 
6 
6 
 
 
83 (74%) 
109 (97%) 
 
 
6 
6 
 
 
0.5 
0.7 
TJC28, median (IQR)                       
SJC28, median (IQR)                       
7 (3613) 
4 (268) 
6 
6 
10 (5617) 
6 (3610) 
6 
6 
6668
668
RAI, median (IQR)                           
SJC44, median (IQR)                       
7 (4610)
5 (369) 
17 
17 
9 (5613)
7 (4613) 
24 
24 
660
660
CRP, median (IQR), mg/L 21 (7645) 6 13 (0640) 6 0.2 
Patient VASDA, median (IQR), 
mm  
50 (31677) 27 61 (35682) 44 0.3 
DAS286CRP3v, median (IQR) 
DAS286CRP4v, median (IQR)         
4.5(3.865.2) 
4.9(4.065.5) 
6 
27 
4.7(3.765.8) 
5.1(3.966.1) 
6 
44 
0.1 
0.5 
DAS446CRP4v, median (IQR)         3.1(2.663.6) 34 3.4(2.664.0) 46 0.1 
HAQ, median (IQR)                          1.3(0.861.9) 30 1.4(0.561.8) 40 0.9 
Ultrasound of 26 joints: 
Total GS score
c 
Total PDA score
c 
Absence of PDA (total PDA
c
=0) 
Absent/minimal PDA (total 
PDA
c
≤1)
 
 
17 (10625) 
3 (068) 
23 (27%) 
34 (40%) 
 
21 
21 
21 
21 
 
19 (12626) 
3 (069) 
55 (28%) 
61 (35%) 
 
33 
33 
33 
33 
 
0.2 
0.9 
0.9 
0.5 
Radiographic erosion in the 
hands and feet, N (%)              
Any 
1987 ACR definition  
2010 ACR/EULAR definition
 
 
 
18 (17%) 
11 (10%) 
9 (9%) 
 
6 
 
 
20 (18%) 
16 (14%) 
9 (8%) 
 
 
2 
2 
2 
 
 
0.8 
0.4 
0.9 
a
Hypertension, hypercholesterolaemia, ischaemic heart disease, cerebrovascular disease, peripheral vascular 
disease, asthma, chronic obstructive airways disease, diabetes, peptic ulcer disease, chronic kidney disease, 
chronic liver disease, epilepsy, demyelination, depression, thyroid dysfunction, cancer. 
b
Osteoarthritis was 
defined according to a consultant rheumatologist diagnosis (i.e. symptoms and signs consistent with 
osteoarthritis). 
c
Sum of GS or PDA semi6quantitative score assessed in 26 joints (GS or PDA graded between 0 
and 3 for each joint, maximum total score 78).  Bold text indicates statistical significance at the level of p<0.05.  
SD: standard deviation, BMI: body mass index, SJC: swollen joint count, RF: rheumatoid factor, ACPA: anti6cyclic 
citrullinated protein antibody, ACR: American College of Rheumatology, EULAR: European League Against 
Rheumatism, RA: rheumatoid arthritis, TJC: tender joint count, RAI: Ritchie Articular Index, CRP: C6reactive 
protein, VASDA: visual analogue scale global disease assessment, DAS286CRP3v: disease activity score using 
3 variables (SJC28, TJC28 and CRP), DAS286CRP4v: disease activity score using 4 variables (SJC28, TJC28, 
CRP and patient VAS global disease assessment), DAS446CRP3v: disease activity score using 3 variables 
(SJC44, RAI and CRP), DAS446CRP4v: disease activity score using 4 variables (SJC44, RAI, CRP and patient 
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VAS global disease assessment), HAQ: Health Assessment Questionnaire, GS: grey scale synovitis, PDA: power 
Doppler activity; N: number. 
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 Early RA 
n=105 
Ongoing Treatment at 12 months, N (%)                          
MTX monotherapy 
SSZ monotherapy 
HCQ monotherapy 
MTX + other DMARD 
2 DMARDs (excluding MTX) 
MTX + SSZ + HCQ 
Biologic therapy 
Referred to Biologics Clinical Trial 
Other DMARD  
Steroid alone 
None 
 
38 (36%) 
3 (3%) 
5 (5%) 
36 (34%) 
1 (1%) 
8 (8%) 
5 (5%) 
2 (2%) 
2 (2%) 
4 (4%) 
1 (1%) 
Ongoing MTX use at 12 months  
Administered orally, N (%)     
Administered subcutaneously, N (%)     
Weekly dose, median (IQR), mg 
 
75 (76%) 
14 (13%) 
25 (20625) 
Receiving significant total steroid dose over 12 months, N (%) 
                                      ≥80mg triamcinolone 
≥150mg prednisolone 
≥120mg methylprednisolone     
 
10 (10%) 
30 (29%) 
84 (80%) 
Total methylprednisolone dose over 12 months, median (IQR), mg 240 (1206360) 
Adherence to treatment to target guidelines, N (%) 
Clinical assessment at least every 3 months until the target for 
treatment (DAS286CRP4v <2.6) was met  
DAS286CRP4v available at least every 3 months until the target 
for treatment (DAS286CRP4v <2.6) was met 
DAS286CRP4v available at least every 3 months and DMARD 
therapy escalated if the target was not met 
DAS286CRP4v available at least every 3 months and DMARD 
or corticosteroid therapy escalated if the target was not met 
 
97 (92%) 
 
76 (72%) 
 
53 (51%) 
 
61 (58%) 
 
MTX: methotrexate, SSZ: sulphasalazine, HCQ: hydroxychloroquine, DMARD: disease6modifying 
anti6rheumatic drug, DAS286CRP4v: disease activity score using 4 variables (SJC28, TJC28, CRP 
and patient VAS global disease assessment). 
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Values are number of patients (percentage of patients), unless otherwise stated. 
a
2011 ACR/EULAR Boolean remission (swollen joint count (SJC44) ≤1, 
tender joint count (TJC53) ≤1, CRP≤10mg/dL and patient VASDA≤10mm). 
b
Sum of PDA semi6quantitative score assessed in 26 joints (PDA graded between 
0 and 3 for each joint, maximum total score 78). PDA: power Doppler activity, PABAK: prevalence and bias adjusted kappa, DAS286CRP4v: disease activity 
score using 4 variables (SJC28, TJC28, CRP and patient VASDA), DAS446CRP4v: disease activ ty score using 4 variables (SJC44, RAI, CRP and patient 
VASDA). 
Clinical 
Outcomes 
Absence of PDA activity in 26 joints 
(total PDA score
b
=0) 
Absent/minimal PDA activity in 26 joints  
(total PDA score
b
≤1) 
Absent/minimal PDA activity in 26 joints  
(total PDA score
b
≤1, excluding PDA=grade 1 in 
the wrists and/or first MTPs) 
Clinical 
and 
imaging 
outcome 
Clinical 
outcome 
only 
Imaging 
outcome 
only 
Neither 
clinical 
nor 
imaging 
outcome 
PABAK 
Clinical 
and 
imaging 
outcome 
Clinical 
outcome 
only 
Imaging 
outcome 
only 
Neither 
clinical 
nor 
imaging 
outcome 
PABAK 
Clinical 
and 
imaging 
outcome 
Clinical 
outcome 
only 
Imaging 
outcome 
only 
Neither 
clinical 
nor 
imaging 
outcome 
PABAK 
DAS286
CRP4v 
remission  
(DAS286
CRP4v<2.6) 
19 
(18%) 
26 
(25%) 
23 
(22%) 
37 
(35%) 
0.07 
28 
(27%) 
17 
(16%) 
32 
(30%) 
28 
(27%) 
0.07 
31 
(30%) 
14 
(13%) 
36 
(34%) 
24 
(23%) 
0.05 
DAS446
CRP4v 
remission 
(DAS446
CRP4v<1.6) 
18 
(17%) 
23 
(22%) 
24 
(23%) 
40 
(38%) 
0.10 
27 
(26%) 
14 
(13%) 
33 
(31%) 
31 
(30%) 
0.10 
29 
(28%) 
12 
(11%) 
38 
(36%) 
26 
(25%) 
0.05 
Boolean 
remission
a 
6  
(6%) 
9  
(9%) 
36 
(34%) 
54 
(51%) 
0.14 
10 
(10%) 
5  
(5%) 
50 
(48%) 
40 
(38%) 
60.05 
10 
(10%) 
5  
(5%) 
57 
(54%) 
33 
(31%) 
60.18 
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 DAS286CRP4v<2.6 DAS446CRP4v<1.6 Boolean Remission
a 
Total PDA score
b
=0 Total PDA score
b
≤1 
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p 
Age 1.01(0.9861.04) NS 1.01(0.9861.04) NS 1.01(0.9661.05) NS 0.98(0.9561.01) NS 0.98(0.9561.01) NS 
Female 0.45(0.1861.11) NS 68;960765<: 668 68096066<7: 662 0.58(0.2461.42) NS 0.63(0.2561.59) NS
BMI 0.94(0.8761.02)
e 
NS 0.96(0.8861.04)
e 
NS 0.94(0.8261.07)
e 
NS 1.01(0.9361.09)
e 
NS 1.00(0.9361.09)
e 
NS 
Symptom duration, 
months 
6<3965;6<<: 668 6<89654066: 667 1.00(0.9261.08) NS 0.99(0.9461.05) NS 1.03(0.9761.10) NS 
Current or previous 
smoker 
0.63(0.2861.39) NS 0.94(0.4262.1) NS 0.66(0.2261.99) NS 1.41(0.6263.17) NS 1.15(0.5262.55) NS 
Number of comorbidities
c
 0.86(0.6361.16) NS 1.02(0.7661.37) NS 0.67(0.4061.13) NS 1.01(0.7561.36) NS 0.89(0.6761.20) NS 
History or current 
evidence of concurrent 
osteoarthritis
d 
0.76(0.3561.67) NS 0.73(0.3361.61) NS 0.83(0.2762.54) NS 62096056<8: 668 0.70(0.3261.52) NS 
RF positive 1.38(0.5663.40) NS 1.12(0.4562.77) NS 0.94(0.2763.26) NS 0.52(0.2161.26) NS 68496026<4: 662 
ACPA positive 1.68(0.6564.37) NS 1.76(0.6664.7) NS 2.10(0.44610.05) NS 0.73(0.2961.84) NS 68;9608066: 667 
SJC28  0.98(0.8961.08) NS 0.97(0.8761.07) NS 1.00(0.8761.14) NS 65796476<;: 666< 655964<6<5: 663 
TJC28 6<8965;6<<: 668 6<696586<4: 666; 65496446<<: 662 0.96(0.9061.03) NS 0.97(0.9161.03) NS
CRP, mg/L 0.99(0.9861.00) NS 0.99(0.9861.00) NS 0.99(0.9861.01) NS 0.99(0.9761.00) NS 6<<96<5066: 668 
Patient VASDA, mm 6<596<;066:

663 0.98(0.9761.00)
f 
NS 0.98(0.9661.00)
f 
NS 0.99(0.9761.01)
f 
NS 0.98(0.9761.00)
f 
NS 
DAS286CRP3v 6;;96276<4: 662 674968565;: 6665 67896866<7: 668 6;;96276<4: 662 67<9626654: 6665
HAQ 62;96386<8:

668 62;96386<7:

662 635960664<:

663 0.65(0.3361.29)
g
NS 0.49(0.2461.01)
g
NS
Total GS score on 
ultrasound
b
 
1.00(0.9661.04)
h 
NS 0.98(0.9461.02)
h 
NS 1.00(0.9561.05)
h 
NS 0.96(0.9261.01)
h 
NS 0.97(0.9361.01)
h 
NS 
Total PDA score on 
ultrasound
b
 
0.98(0.9261.05)
h 
NS 0.97(0.9161.04)
h 
NS 0.98(0.8961.07)
h 
NS 65<96506<4:
 
660 65496566<7:
 
6663 
Radiographic erosions 0.82(0.2962.32) NS 1.31(0.4763.65) NS 1.97(0.5567.09) NS 0.37(0.1161.21) NS 0.41(0.1461.16) NS 
a
2011 ACR/EULAR Boolean remission (swollen joint count (SJC44) ≤1, tender joint count (TJC53) ≤1, CRP≤10mg/dL and patient VASDA≤10mm). 
b
Sum of GS or PDA semi6
quantitative score assessed in 26 joints (GS or PDA graded between 0 and 3 for each joint, maximum total score 78). 
c
Any of:  hypertension, hypercholesterolaemia, ischaemic 
heart disease, cerebrovascular disease, peripheral vascular disease, asthma, chronic obstructive airways disease, diabetes, peptic ulcer disease, chronic kidney disease, 
chronic liver disease, epilepsy, demyelination, depression, thyroid dysfunction or cancer. 
d
Osteoarthritis was defined according to a consultant rheumatologist diagnosis (i.e. 
symptoms and signs consistent with osteoarthritis). Missing data in 
e
13, 
f
27, 
g
30 and 
h
21 cases. Bold text indicates statistical significance at the level of p<0.05.  
OR: odds ratio, CI: confidence interval, NS: not significant, BMI: body mass index, RF: rheumatoid factor, ACPA: anti6citrullinated protein antibody, TJC: tender joint count, 
SJC: swollen joint count, CRP: C6reactive protein, VASDA: visual analogue scale global disease assessment, DAS286CRP3v: disease activity score using 3 variables (SJC28, 
TJC28 and CRP), HAQ: health assessment questionnaire, GS: grey scale synovitis, PDA: power Doppler activity. 
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Outcome at 12 months Baseline Variable OR (95% CI) p Missing Cases 
DAS286CRP4v<2.6 
Symptom duration, months 6<696506<<: 662
37 
TJC28 0.93(0.8561.02) NS 
Patient VASDA, mm 0.98(0.9561.00) NS 
HAQ 0.71(0.2661.93) NS 
DAS446CRP4v<1.6 
Female 633966;644: 663
30 
Symptom duration, months 0.93(0.8561.02) NS 
TJC28 655964<6<5: 663
HAQ 0.53(0.2361.26) NS 
Boolean Remission
a
 
Female 0.35(0.0861.50) NS 
30 TJC28 0.91(0.7961.05) NS 
HAQ 68896006<5: 667
Total PDA score
b
=0 
History or current evidence of concurrent osteoarthritis
c 
68796086<8: 662
21 SJC28 0.89(0.7761.03) NS 
Total PDA score
b 
0.92(0.8361.02) NS 
Total PDA score
b
≤1 
RF positivity 0.59(0.1562.29) NS 
21 
ACPA positivity 0.54(0.1462.07) NS 
SJC28 0.99(0.8661.13) NS 
CRP 0.99(0.9861.01) NS 
Total PDA score
b 
65<96506<5: 660
a
2011 ACR/EULAR Boolean remission (swollen joint count (SJC44) ≤1, tender joint count (TJC53) ≤1, CRP≤10mg/dL and patient VASDA ≤10mm). 
b
Sum of 
PDA semi6quantitative score assessed in 26 joints (PDA graded between 0 and 3 for each joint, maximum total score 78). 
c
Osteoarthritis was defined 
according to a consultant rheumatologist diagnosis (i.e. symptoms and signs consistent with osteoarthritis). Bold text indicates statistical significance at the 
level of p<0.05.  OR: odds ratio, CI: confidence interval, NS: not significant, TJC: tender joint count, VASDA: visual analogue scale global disease 
assessment, HAQ: health assessment questionnaire, SJC: swollen joint count, PDA: power Doppler activity, RF: rheumatoid factor, ACPA: anti6citrullinated 
protein antibody, CRP: C6reactive protein. 

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